Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping.

OGM aquired aberrations balanced translocations chromosomal aberrations cytogenetics hematological malignancies leukemia optical genome mapping somatic aberrations structural variants

Journal

American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475

Informations de publication

Date de publication:
05 08 2021
Historique:
received: 01 10 2020
accepted: 01 06 2021
pubmed: 9 7 2021
medline: 31 8 2021
entrez: 8 7 2021
Statut: ppublish

Résumé

Somatic structural variants (SVs) are important drivers of cancer development and progression. In a diagnostic set-up, especially for hematological malignancies, the comprehensive analysis of all SVs in a given sample still requires a combination of cytogenetic techniques, including karyotyping, FISH, and CNV microarrays. We hypothesize that the combination of these classical approaches could be replaced by optical genome mapping (OGM). Samples from 52 individuals with a clinical diagnosis of a hematological malignancy, divided into simple (<5 aberrations, n = 36) and complex (≥5 aberrations, n = 16) cases, were processed for OGM, reaching on average: 283-fold genome coverage. OGM called a total of 918 high-confidence SVs per sample, of which, on average, 13 were rare and >100 kb. In addition, on average, 73 CNVs were called per sample, of which six were >5 Mb. For the 36 simple cases, all clinically reported aberrations were detected, including deletions, insertions, inversions, aneuploidies, and translocations. For the 16 complex cases, results were largely concordant between standard-of-care and OGM, but OGM often revealed higher complexity than previously recognized. Detailed technical comparison with standard-of-care tests showed high analytical validity of OGM, resulting in a sensitivity of 100% and a positive predictive value of >80%. Importantly, OGM resulted in a more complete assessment than any previous single test and most likely reported the most accurate underlying genomic architecture (e.g., for complex translocations, chromoanagenesis, and marker chromosomes). In conclusion, the excellent concordance of OGM with diagnostic standard assays demonstrates its potential to replace classical cytogenetic tests as well as to rapidly map novel leukemia drivers.

Identifiants

pubmed: 34237281
pii: S0002-9297(21)00223-8
doi: 10.1016/j.ajhg.2021.06.001
pmc: PMC8387283
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1423-1435

Informations de copyright

Copyright © 2021 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Références

Cell Rep. 2018 Apr 3;23(1):227-238.e3
pubmed: 29617662
Nat Commun. 2019 Mar 4;10(1):1025
pubmed: 30833565
Genet Med. 2016 Jun;18(6):635-42
pubmed: 27124785
Oncotarget. 2017 Apr 4;8(14):23588-23602
pubmed: 28423598
G3 (Bethesda). 2019 Jun 5;9(6):1795-1805
pubmed: 30996023
Cancer Res. 2003 Mar 15;63(6):1202-6
pubmed: 12649177
Genet Med. 2017 Sep;19(9):1055-1063
pubmed: 28333917
Lancet. 1997 Aug 16;350(9076):485-7
pubmed: 9274585
Neoplasma. 2016;63(1):150-7
pubmed: 26639245
Nat Genet. 2017 Apr;49(4):643-650
pubmed: 28263316
Nature. 2012 Aug 2;488(7409):49-56
pubmed: 22832581
Nat Commun. 2016 Jun 30;7:12065
pubmed: 27356984
Semin Cell Dev Biol. 2021 Feb 16;:
pubmed: 33608210
Nat Biotechnol. 2012 Aug;30(8):771-6
pubmed: 22797562
Genome Res. 2019 Jul;29(7):1178-1187
pubmed: 31186302
Nat Biotechnol. 2020 Nov;38(11):1347-1355
pubmed: 32541955
Eur J Hum Genet. 2003 Sep;11(9):643-51
pubmed: 12939649
Genet Med. 2018 Jan;20(1):159-163
pubmed: 28640241
Nat Methods. 2018 Jun;15(6):461-468
pubmed: 29713083
Genes Chromosomes Cancer. 2016 May;55(5):480-91
pubmed: 26774012
Nature. 2017 Jun 22;546(7659):524-527
pubmed: 28605751
Adv Exp Med Biol. 2019;1129:97-118
pubmed: 30968363
Ann N Y Acad Sci. 2016 Jul;1376(1):14-7
pubmed: 27525383
Genome Biol. 2011 Oct 19;12(10):R103
pubmed: 22014273
Genome Res. 2017 Feb;27(2):185-195
pubmed: 27903646
Brain. 2012 Apr;135(Pt 4):1027-41
pubmed: 22427331
Cancer Genet. 2018 Dec;228-229:218-235
pubmed: 30344013
Semin Hematol. 2014 Oct;51(4):250-8
pubmed: 25311738
Leukemia. 2019 Aug;33(8):1851-1867
pubmed: 30696948
Leukemia. 2007 Jul;21(7):1532-44
pubmed: 17495977
Nat Commun. 2017 Nov 6;8(1):1326
pubmed: 29109544
Nat Med. 2010 Aug;16(8):903-8
pubmed: 20616797
Science. 1993 Oct 1;262(5130):110-4
pubmed: 8211116
Nat Commun. 2020 Sep 1;11(1):4374
pubmed: 32873787
Nature. 2016 Oct 13;538(7624):243-247
pubmed: 27706134
N Engl J Med. 2021 Mar 11;384(10):924-935
pubmed: 33704937
Methods Mol Biol. 2018;1833:193-203
pubmed: 30039375
Genome Med. 2017 Oct 25;9(1):90
pubmed: 29070057
Science. 2021 Apr 2;372(6537):
pubmed: 33632895
J Pers Med. 2021 Feb 18;11(2):
pubmed: 33670576
Nat Commun. 2019 Apr 16;10(1):1784
pubmed: 30992455
Genetics. 2016 Jan;202(1):351-62
pubmed: 26510793

Auteurs

Kornelia Neveling (K)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands; Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

Tuomo Mantere (T)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands; Radboud Institute of Medical Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, Oulu, Finland.

Susan Vermeulen (S)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Michiel Oorsprong (M)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Ronald van Beek (R)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Ellen Kater-Baats (E)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Marc Pauper (M)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Guillaume van der Zande (G)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Dominique Smeets (D)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Daniel Olde Weghuis (DO)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Marian J P L Stevens-Kroef (MJPL)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands.

Alexander Hoischen (A)

Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500 HB, the Netherlands; Radboud Institute of Medical Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6532 GA Nijmegen, the Netherlands. Electronic address: alexander.hoischen@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH